Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial | BMC Cancer | Full Text

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial | BMC Cancer | Full Text

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial

Optimal management strategies for clinically localised prostate cancer are debated. Using median 10-year data from the largest randomised controlled trial to date (ProtecT), the lifetime cost-effectiveness of ...

Authors:S. Sanghera, S. Mohiuddin, J. Coast, K. Garfield, S. Noble, C. Metcalfe, J. A. Lane, E. L. Turner, D. Neal, F. C. Hamdy, R. M. Martin and J. L. Donovan

Citation:BMC Cancer 2020 20:971

Content type:Research article

 

Published on: 7 October 2020

• ViewFull Text
 
• ViewPDF